Ethinyl estradiol sulfonate
 | |
| Clinical data | |
|---|---|
| Trade names | Turisteron |
| Routes of administration | Oral, intramuscular injection |
| Identifiers | |
| |
| CAS Number | 28913-23-7 |
| PubChem (CID) | 68582 |
| ChemSpider | 61851 |
| UNII | XF48685MYR |
| KEGG | D07928 |
| Chemical and physical data | |
| Formula | C23H30O4S |
| Molar mass | 402.5469 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Ethinyl estradiol sulfonate (EES) (brand name Turisteron), also known as ethinyl estradiol isopropylsulfonate or ethinyl estradiol propanesulfate, as well as 17α-ethinyl-3-isopropylsulfonyloxyestradiol, is a synthetic, steroidal estrogen that is marketed in Germany.[1][2] It is an ester of ethinyl estradiol, and acts as a long-acting (half-life of six days),[3] orally active depot form of the drug.[2] EES is used in the treatment of advanced breast and prostate cancers.[2][3][4][5] The drug is very potent (used clinically at a dosage of 1–2 mg weekly via intramuscular injection) and a powerful antigonadotropin, capable of suppressing circulating testosterone concentrations to levels comparable to those seen with castration (less than 1–3% of initial values).[5][6] As such, EES is a strong functional antiandrogen.[7]
See also
References
- ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 412–. ISBN 978-3-88763-075-1.
- 1 2 3 Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 540–542. doi:10.1007/978-3-642-60107-1. ISBN 978-3-642-60107-1.
- 1 2 Gürtler R, Tanneberger S, Bodek B, Morack G (1982). "[Clinical experience with the depot estrogen Turisteron in the treatment of metastatic breast cancer (author's transl)]". Arch. Geschwulstforsch. (in German). 52 (2): 129–39. PMID 7103689.
- ↑ S. Monfardini; K. Brunner; D. Crowther; S. Eckhardt; D. Olive; S. Tanneberger; A. Veronesi; J.M.A. Whitehouse; R. Wittes (1987). Manual of Adult and Paediatric Medical Oncology. Springer Science & Business Media. pp. 196–. doi:10.1007/978-3-642-82489-0. ISBN 978-3-642-82489-0.
- 1 2 Dörner G, Schnorr D, Stahl F, Rohde W (1985). "Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron)". Exp. Clin. Endocrinol. 86 (2): 190–6. doi:10.1055/s-0029-1210486. PMID 3912197.
- ↑ Stahl F, Schnorr D, Bär CM, Fröhlich G, Dörner G (1989). "Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer". Exp. Clin. Endocrinol. 94 (3): 239–43. doi:10.1055/s-0029-1210905. PMID 2630306.
- ↑ Schnorr D, Dörner G, Stahl F, Rohde W, Guddat HM (1987). "[Conservative therapy of prostate cancer using Turisteron]". Z Urol Nephrol (in German). 80 (3): 149–57. PMID 3111122.